Gene Synthesis Market by Product, Method, Gene Type, Application, End-use

List of Tables

[181 Pages Report] The Gene Synthesis Market size was estimated at USD 4.24 billion in 2023 and expected to reach USD 4.68 billion in 2024, at a CAGR 10.82% to reach USD 8.70 billion by 2030.

The gene synthesis market comprises technologies, products, and services related to the artificial creation of DNA sequences through chemical methods in various industries such as research, medicine, agriculture, and biotechnology. Key end-users include academic institutions, pharmaceutical and biotechnology companies, government agencies, and contract research organizations (CROs). The growing prevalence of chronic conditions among the global population and rising demand for personalized medicines, along with advancements in genomics research, are driving this market. Moreover, the advantage of gene synthesis over traditional methods is fueling market growth. However, strict regulations governing the development and commercialization of GMOs and technical challenges such as limitations in size and complexity of synthetic genes limit the growth of the gene synthesis market. Emerging technologies in gene synthesis for efficiency and accuracy and the growing utilization of gene synthesis in energy and agriculture industries are creating significant growth opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.24 billion
Estimated Year [2024]	USD 4.68 billion
Forecast Year [2030]	USD 8.70 billion
CAGR (%)	10.82%

Product: Expanding usage of software that helps design synthetic genes accurately

Gene synthesis hardware, including oligonucleotide synthesizers, are specialized instruments used for the synthesis of short DNA or RNA fragments called oligonucleotides. These synthesizers are essential in the initial steps of gene synthesis, creating the building blocks that will be assembled into longer gene sequences. Gene sequencers are critical for this purpose, providing high-throughput and accurate sequencing capabilities to ensure the synthetic genes match the intended design. Automated liquid handling systems are employed to reduce errors and increase throughput during the pipetting, dilution, and mixing of reagents and oligonucleotides necessary for assembly and amplification steps. Gene synthesis services involve the production of synthetic DNA sequences that can be customized to cater to specific research or industrial requirements. These services are essential for various applications such as protein production, antibody engineering, vaccine development, and biofuel research. The growing demand for custom-made genes has led to an increase in service providers offering end-to-end solutions in gene synthesis. Software solutions are designed specifically for designing and simulating synthetic genes. These tools allow researchers and biotechnologists to streamline their workflow by optimizing factors such as codon usage bias, RNA secondary structure prediction, GC content, and restriction enzyme site avoidance. Moreover, gene synthesis software helps reduce the risk of errors during de novo DNA synthesis, thereby improving research efficiency and minimizing costs.

Method: Rising utilization of chip-based synthesis for large-scale projects

Chip-based synthesis uses microarrays or biochips to synthesize thousands of oligonucleotides simultaneously on a small glass slide. This high-throughput method is suitable for large-scale projects requiring multiple genes or when cost-efficiency is crucial. PCR-based enzyme synthesis involves using enzymes such as DNA polymerase to assemble short overlapping oligonucleotides into full-length genes through consecutive rounds of PCR amplification. This method offers quick turnaround times and is ideal for small-scale projects focusing on single genes or gene variants. Solid-phase synthesis involves sequentially adding nucleotides to a growing DNA chain immobilized on a solid support. This method offers high fidelity and can generate long DNA sequences with fewer errors than other methods. Chip-based synthesis is best suited for large-scale projects requiring cost efficiency. PCR-based enzyme synthesis is ideal when rapid turnaround times are essential for small-scale projects focusing on single genes or gene variants, while solid-phase synthesis is preferred when high fidelity and longer DNA sequences are required.

Gene Type: Growing potential for express gene synthesis that provides quick access to shorter genes for time-sensitive projects

Complex gene synthesis focuses on creating synthetic genes that contain challenging sequences, such as high GC content, tandem repeats, and homopolymeric regions. Scientists often require these genes for advanced research in therapeutic applications such as vaccine development, pathway engineering, and enzymatic optimization. Express gene synthesis caters to scientists who require fast turnaround times for small-scale projects or proof-of-concept studies. These synthesized genes are shorter in length and have a quicker turnaround time compared to other types of gene synthesis. Standard gene synthesis involves the synthesis of high-quality, error-free DNA sequences using a variety of techniques, including oligonucleotide assembly and error correction. This type is most commonly used in routine molecular biology projects involving cloning, expression analysis, and recombinant protein production.

End-use: Increasing focus on innovative drug discovery and therapeutic development across biotechnology and pharmaceutical companies

Academic and government research institutes significantly contribute to gene synthesis market demand because they focus on basic research, therapeutic development, and genetic engineering advancements. These institutes utilize gene synthesis services to generate custom DNA sequences, design biological pathways, and perform targeted gene modifications. Biotechnology and pharmaceutical companies rely heavily on gene synthesis services for drug discovery, therapeutic development, and precision medicine advancements. Custom genes facilitate protein expression studies, identification of novel drug targets, and development of disease-specific animal models. Contract research organizations have emerged as vital end-users of gene synthesis services, supporting biopharmaceutical and academic clients in gene library construction, custom cloning, and protein expression optimization. Biotechnology and pharmaceutical companies command the largest share due to their focus on innovative drug discovery and therapeutic development. Academic government research institutes follow closely, emphasizing fundamental research and genetic engineering advancements. CROs are experiencing rapid growth by offering comprehensive genomics solutions that cater to diverse client demands across industries.

Gene Type: Growing potential of express genes that are optimized for high levels of expression in specific host organisms

Complex genes are characterized by their intricate nucleotide sequences, which often include high GC content, repeated sequences, or sequences prone to secondary structures. Such complexities can pose challenges during the synthesis process and subsequent cloning. Genes with long homopolymeric runs or cryptic splice sites are also considered complex. Synthesizing complex genes requires advanced techniques and careful design to ensure the fidelity and functionality of the final product. Express genes refer to synthetically manufactured DNA sequences optimized for high levels of expression in specific host organisms. These gene variants usually undergo codon optimization, where codons are modified to match the preferred usage of the expression system, leading to more efficient translation of the mRNA into proteins. Additionally, express genes can be outfitted with strong promoters, enhancers, and other regulatory elements to boost protein production for research or industrial enzyme applications. Standard genes are synthetic DNA sequences that represent the basic offering in gene synthesis services. The genes do not possess the complexities found in complex genes and are not optimized for overexpression, including express genes. Instead, standard genes provide researchers with accurate, reliable, and cost-effective means to obtain DNA sequences that are reflective of the native DNA sequence or include slight modifications for cloning or functional analysis. Standard genes are the backbone of many genetic engineering projects and are widely used across different domains of life sciences.

Regional Insights

The gene synthesis market in the Americas is highly developing owing to the presence of a developed healthcare sector and supportive government programs, which has resulted in considerable product development and the commercialization of gene synthesis technologies in the United States and Canada. This is attributed to growing improvements in R&D facilities, available disposable income, and rapidly developing economic conditions. Moreover, federal agencies and authorities have launched several initiatives, programs, and schemes to encourage gene therapy research in the region, creating a platform for gene synthesis in the Americas. Emerging economies such as India, China, Singapore, and Malaysia are potential markets for market expansion due to improved healthcare standards. These economies have a considerable presence of domestic manufacturers of gene synthesis, which contributes to an upsurge in the market penetration of multinational giants. The growing prevalence of chronic diseases, increasing technological advancements, and improved healthcare infrastructure are the primary reasons driving the gene synthesis market in EMEA. Governments across the region have been continuously investing in gene therapies, thereby expanding the utilization of various gene syntheses. In February 2022, the Dutch government invested USD 55.04 million to build a new national pilot factory to advance the development and manufacturing of promising cell and gene therapies. The investment by the Dutch government is expected to provide excellent opportunities for cell and gene therapy companies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gene Synthesis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gene Synthesis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gene Synthesis Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Ansa Biotechnologies, Inc., Applied Biological Materials Inc., AstraZeneca PLC, Azenta, Inc., Barcode Biosciences Private Limited, BGI Genomics by BGI Group, BioCat GmbH by AddLife AB, Biomatik Corporation, Bioneer Corporation, Biotage AB, Biotech Desk Pvt. Ltd., Boster Biological Technology, Brooks Automation Inc., Camena Bioscience, Charles River Laboratories International, Inc., Constructive Bio Ltd, Creative Biogene, Danaher Corporation, DNA TwoPointO Inc., Elabscience Biotechnology Inc., Elegen Corp., Eurofins Scientific SE, Evonetix Ltd., GenCefe Biotech Limited, Gene Universal, Inc., General Biosystems, Inc., GenScript Biotech Corporation, Ginkgo Bioworks Holdings, Inc., Macrogen, Inc., Merck KGaA, NZYTech, Lda., OriGene Technologies, Inc., ProMab Biotechnologies, Inc., ProteoGenix SAS, QIAGEN N.V., Synbio Technologies LLC, Telesis Bio Inc., Thermo Fisher Scientific Inc., and Twist Bioscience Corporation.

Market Segmentation & Coverage

This research report categorizes the Gene Synthesis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Hardware
- Services
  - Antibody DNA Synthesis
  - Viral DNA Synthesis

Software

Method
- Chip-Based Synthesis
- PCR-Based Enzyme Synthesis
- Solid-Phase Synthesis

Gene Type
- Complex Gene
- Express Gene
- Standard Gene

Application
- Disease Diagnosis
- Gene & Cell Therapy Development
- Vaccine Development

End-use
- Academic & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gene Synthesis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gene Synthesis Market?

3. What are the technology trends and regulatory frameworks in the Gene Synthesis Market?

4. What is the market share of the leading vendors in the Gene Synthesis Market?

5. Which modes and strategic moves are suitable for entering the Gene Synthesis Market?

Product Code: MRR-3A2E844FEB5F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of chronic conditions among the global population
  - 5.1.1.2. Increasing genomics research activities and rising focus on personalized medicines
  - 5.1.1.3. Growing investments by the private and public sectors in pharmaceutical research
- 5.1.2. Restraints
  - 5.1.2.1. Strict regulations governing gene synthesis and high cost associated with the process
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging new technologies in gene synthesis
  - 5.1.3.2. Utilization of gene synthesis in energy and agriculture industries
- 5.1.4. Challenges
  - 5.1.4.1. Limitations in size and complexity of synthetic genes
5.2. Market Segmentation Analysis
- 5.2.1. Product: Expanding usage of software that helps design synthetic genes accurately
- 5.2.2. Method: Rising utilization of chip-based synthesis for large-scale projects
- 5.2.3. Gene Type: Growing potential for express gene synthesis that provides quick access to shorter genes for time-sensitive projects
- 5.2.4. End-use: Increasing focus on innovative drug discovery and therapeutic development across biotechnology and pharmaceutical companies
- 5.2.5. Gene Type: Growing potential of express genes that are optimized for high levels of expression in specific host organisms
5.3. Market Trend Analysis
- 5.3.1. Ongoing technological advancements to increase the speed of synthetic gene production coupled with a strong foothold of major players in the Americas region
- 5.3.2. Robust R&D activities in biotechnology and pharmaceutical sectors and the rising need for synthetic gene applications in the Asia-Pacific
- 5.3.3. Supportive government initiatives for genomic projects and advancing use of gene synthesis in agricultural sector in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Gene Synthesis Market, by Product

6.1. Introduction
6.2. Hardware
6.3. Services
6.4. Software

7. Gene Synthesis Market, by Method

7.1. Introduction
7.2. Chip-Based Synthesis
7.3. PCR-Based Enzyme Synthesis
7.4. Solid-Phase Synthesis

8. Gene Synthesis Market, by Gene Type

8.1. Introduction
8.2. Complex Gene
8.3. Express Gene
8.4. Standard Gene

9. Gene Synthesis Market, by Application

9.1. Introduction
9.2. Disease Diagnosis
9.3. Gene & Cell Therapy Development
9.4. Vaccine Development

10. Gene Synthesis Market, by End-use

10.1. Introduction
10.2. Academic & Government Research Institutes
10.3. Biotechnology & Pharmaceutical Companies
10.4. Contract Research Organizations

11. Americas Gene Synthesis Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Gene Synthesis Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Gene Synthesis Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Evonetix and Analog Devices Inc To Progress Revolutionary Gene Synthesis Platform
- 14.3.2. Gyros Protein Technologies and Biotage Partner to Advance Peptide Purification Efficiency With New Automated Solution
- 14.3.3. Synplogen and Ginkgo Bioworks Announce Plans to Accelerate Global DNA Manufacturing and Gene Therapy Platform Services in Japan
- 14.3.4. Twist Bioscience Launches Express Genes Rapid Gene Synthesis Service
- 14.3.5. Biotech Firm Closes GBP 5.6 million Seed Financing
- 14.3.6. Bruker to Buy PhenomeX For USD 108 Million
- 14.3.7. Series Funding to Support Expansion of DNA Synthesis Technology
- 14.3.8. NunaBio Raises GBP 1.9M In Seed Funding To Expand Infrastructure And Accelerate R&D
- 14.3.9. Elegen Launches ENFINIA DNA, Rapid Long DNA Synthesis to Power the Bioeconomy
- 14.3.10. Ansa Biotechnologies Announces Successful de novo Synthesis of Oligonucleotide at 1005 Bases
- 14.3.11. GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service
- 14.3.12. Evonetix Closes USD 24 million Financing
- 14.3.13. Gene Synthesis (End-to-End) Now In India At Barcode Biosciences
- 14.3.14. Eurofins Genomics Blue Heron launches IVT mRNA Synthesis Service: The Future of Gene Expression

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio